1 / 40

Histiocytic Syndromes

Histiocytic Syndromes. Dendritic cell-related disorders Langerhans cells histiocytosis juvenile xanthogranuloma Macrophage-related disorders primary hemophagocytic syndromes (familial, sporadic) secondary hemophagocytic syndromes (viral, other) Malignant disorders monocytic leukemias

Download Presentation

Histiocytic Syndromes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Histiocytic Syndromes • Dendritic cell-related disorders • Langerhans cells histiocytosis • juvenile xanthogranuloma • Macrophage-related disorders • primary hemophagocytic syndromes (familial, sporadic) • secondary hemophagocytic syndromes (viral, other) • Malignant disorders • monocytic leukemias • malignant histiocytosis

  2. Langerhans Cell Histiocytosis Epidemiology • Incidence: • 5 cases/million population/yr (childhood LCH) • incidence of adult LCH is unknown • more common in males than females (1.3 : 1) • average age at onset: 1.8 years

  3. Langerhans Cell Histiocytosis: Historical Syndromes • eosinophilic granuloma: isolated lytic lesion of bone or soft tissue mass • Hand-Schuller-Christian disease: skull lesions, exophthalmos, and DI (1893) • Letterer-Siwe disease: seborrheic rash, hepatosplenomegaly, lung involvement in infants (1924) • the spectrum of “Histiocytosis X” (1953)

  4. Langerhans cells • described by Paul Langerhans (medical student) in 1868 • Langerhans cells (LC) reside in the epidermis (1-2% epidermal cells) & lung • LCs process antigens for presentation to T cells after migrating to lymph nodes • LCs contain Birbeck granules, and express CD1a and S-100 • LCs associated with “Histiocytosis X” in 1973 (Nezelof et al)

  5. Generation of Langerhans cells • LCs can be generated from stem cells: • obtain CD34+ stem cells • incubate w/ GM-CSF and TNF-alpha for 3 weeks • resulting cells have Birbeck granules and express CD1a • have functional characteristics of LC’s

  6. Langerhans Cell Histiocytosis: Pathology • a clonal proliferation of Langerhans cells • LCs do not show dysplasia or atypia (features of malignant cells) • LCH lesions contain LCs, macrophages, T cells, eosinophils, and granulocytes • LCs associated with “Histiocytosis X” in 1973 (Nezelof et al)

  7. Langerhans Cell Histiocytosis: Clinical manifestations I • painful swelling of bones • unifocal bony lesion (31% at presentation) • isolated multifocal bone involvement (19%) • persistent otitis / mastoiditis • mandible involvement (“floating teeth”) • papular rash (37% at presentation) • hepatosplenomegaly • lymphadenopathy

  8. Langerhans Cell Histiocytosis: Clinical manifestations II • pulmonary involvement (interstitial pattern -> “honeycombing”) • marrow involvement (cytopenias) • GI involvement (diarrhea, malabsorption) • endocrine involvement: • diabetes insipidus • growth failure • hypothyroidism

  9. Langerhans Cell Histiocytosis: Extent of disease at diagnosis • single system / single site 33% • single system / multiple sites 15% • multisystem involvement 52%

  10. Langerhans Cell Histiocytosis: Diagnostic criteria (Histiocyte Society, 1987) • Presumptive diagnosis • light morphology • Designated diagnosis • light morphology, plus • two or more positive stains for ATPase, S-100, a-D-mannosidase, peanut lectin • Definitive diagnosis • light morphology, plus • Birbeck granules and/or CD1a staining

  11. Langerhans Cell Histiocytosis: Natural history • isolated skin involvement (“Hashimoto-Pritzker disease”): spontaneous resolution • eosinophilic granuloma: may resolve or progress; responds to biopsy, curettage • Hand-Schuller-Christian disease: usually fatal if untreated due to DI • Letterer-Siwe disease: usually fatal if untreated

  12. Langerhans Cell Histiocytosis: Therapeutic modalities • biopsy or curettage • radiation therapy (low dose) • topical steroids • intralesional steroid injections • oral or intravenous steroids • oral or intravenous chemotherapy • single agents (vinblastine, etoposide) • combination chemotherapy

  13. LCH-I: Design • first international clinical trial for LCH • compared vinblastine vs etoposide when given with steroids • enrolled 447 pts from 1991-1995 • 143 randomized pts with multisystem disease

  14. LCH- I

  15. DAL HX-83 and HX-90 studies: Design • two multi-center, non-randomized trials in Austria, Germany, Netherlands and Switzerland • risk-adapted assignment to treatment • intensive induction and continuation therapy (much like leukemia therapy) • total duration of therapy was 12 months

  16. LCH-II • compared vinblastine/prednisone +/- etoposide as induction therapy • continuation therapy: 6-MP, with pulses of induction therapy agents • total duration of therapy was 24 weeks • enrolled 697 pts from 1996-2000 • stratified patients on basis of risk

  17. LCH-II: Risk stratification • “Risk” patients: involvement of liver, spleen, lungs, bone marrow; age < 2 yrs • “Low-risk” patients: none of the above

  18. DAL HX, LCH-I and LCH-II: Conclusions • overall survival of multi-system patients was about 80% on all studies • patients with lack of response at week 12 have a high risk of poor outcome • 20% of patients do not respond to current therapy -> new treatments needed • prolonged therapy has potential benefit

  19. LCH-III: Overall Goals • to deliver risk-adapted therapy • to evaluate response in various risk groups • to assess morbidity in various risk groups

  20. LCH-III: Design • adds methotrexate for “risk” patients • adds stratifications for multifocal bone only patients and CNS patients • patients with involvement of facial bones or middle cranial fossa have 3-fold risk for DI

  21. LCH in Adults • most adults with LCH have pulmonary LCH • most are smokers • symptoms: cough, shortness of breath, chest pain, sputum production, pneumothoraces • CXR: diffuse bilateral infiltrates -> progress to cyst formation and “honeycombing” • Treatment: reports that 2-CdA is effective

  22. Adults Some lesions are not clonal LC cells more mature: CD86+ No IL-10 in macrophages Children All lesions are clonal LC cells less mature: CD86- IL-10 expressed in macrophages LCHChildren vs Adults

  23. Treatment Options for Recurrent/Refractory LCH • Other chemo (Ara-C, methotrexate, cytoxan) • cyclosporine • interferon • retinoic acid (France) • thalidomide (Texas Children’s Cancer Ctr) • allogeneic bone marrow transplantation • 2-chlorodeoxyadenosine (2-CdA) +/- Ara-C

  24. 2-CdA for refractory LCH • Review: 27 pts with refractory LCH were treated with 2CdA (23) or 2-DCF (4) • Doses: 0.1 mg/kg/d - 13 mg/m2/day x 5-7 days for 1-6 courses • Results: 15 CR, 5 PR, 5 NR; no toxic deaths • Toxicities: myelosuppression, prolonged thrombocytopenia, peripheral neuropathies

  25. LCH-S-98: Salvage trial • for pts with relapsed or refractory LCH • must have failed multi-agent therapy and have high-risk disease • 2-CdA 5 mg/m2/day x 5 days q 3 wks x 6 courses • next salvage trial will add low-dose Ara-C to this dose of 2-CdA

  26. Langerhans Cell Histiocytosis: Why does it happen? • Epidemiologic study of possible risk factors published in 1997 • conducted in conjunction with HAA • 22-page self-administered questionnaire • parents of 900 LCH patients in HAA • 63% response rate • 459 patients met all eligibility criteria

  27. Langerhans Cell Histiocytosis: Study of risk factors • Possible associations: • neonatal infections (cause or effect?) • exposure to solvents (acetone) • thyroid disease in family members • No association: • in utero exposure to cigarette smoke • maternal infections or medications

  28. Langerhans Cell Histiocytosis: Challenges for the Future • Better understanding of histiocyte biology • differences between normal LC’s, LCH • differences between localized, extensive LCH • differences between childhood, adult LCH • Better understanding of LCH epidemiology • genetic and environmental factors

  29. Langerhans Cell Histiocytosis: Challenges for the Future • New treatments for both newly diagnosed and relapsed patients • more effective • fewer side effects • “targeted” therapy (CD1a-linked radioisotope)

More Related